Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity

被引：0
|
作者：
Jiawei Yue
Hui Guo
Peng Xu
Jinhong Ma
Weifeng Shi
Yumin Wu
机构：
[1] The Third Affiliated Hospital of Soochow University,Department of Orthopaedics
[2] The Third Affiliated Hospital of Soochow University,Department of Laboratory Medicine
[3] Institute of Nano and Soft Materials (FUNSOM) College of Nano Science &Technology (CNST) Suzhou,Jiangsu Key Laboratory for Carbon
来源：
Cancer Immunology, Immunotherapy | / 73卷
关键词：
Group 2 innate lymphoid cells; Interleukin-33; Cancer immunotherapy; Mature ILC2; Programmed cell death protein-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma
    Krykbaeva, I.
    Damsky, W.
    Turner, N.
    Perry, C.
    Kluger, H.
    Bosenberg, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : B19 - B19
  • [42] A first-in-class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade
    Kim, Jun Gyu
    Ryu, Ki Moon
    Jang, Mi Yeon
    Cho, Jongho
    Kim, Dajeong
    Seong, Dae Hyeon
    Kim, Kyu Hwan
    Jang, Ik-Soo
    Shin, Jeong Yoon
    Han, Hong Sik
    Hwang, Joon Yonug
    Lee, Dae Young
    Ryu, Chae Lim
    Lee, Song Yi
    Han, Tae-Dong
    Yang, SeungMin
    Doh, Hyounmie
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [43] Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade
    Jiang, Yuying
    Yang, Yongbing
    Hu, Yingchao
    Yang, Rui
    Huang, Jiajia
    Liu, Yi
    Wu, Yuqing
    Li, Sheng
    Ma, Chunmei
    Humphries, Fiachra
    Wang, Bingwei
    Wang, Xi
    Hu, Zhibin
    Yang, Shuo
    CELL REPORTS, 2022, 41 (04):
  • [44] SAA suppresses α-PD-1 induced anti-tumor immunity by driving TH2 polarization in lung adenocarcinoma
    Wang, Xin
    Wen, Shaodi
    Du, Xiaoyue
    Zhang, Yihan
    Yang, Xiao
    Zou, Renrui
    Feng, Bing
    Fu, Xiao
    Jiang, Feng
    Zhou, Guoren
    Liu, Zi
    Zhu, Wei
    Ma, Rong
    Feng, Jifeng
    Shen, Bo
    CELL DEATH & DISEASE, 2023, 14 (11)
  • [45] IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation
    Dowling, John P. P.
    Nikitin, Pavel A. A.
    Shen, Fang
    Shukla, Halley
    Finn, James P. P.
    Patel, Nirja
    Swider, Cezary
    Bingaman-Steele, Jamie L. L.
    Nicolescu, Chris
    Sikorski, Eden L.
    Greenawalt, Evan J. J.
    Morin, Michael J. J.
    Robinson, Matthew K. K.
    Lundgren, Karen
    Harman, Benjamin C. C.
    MABS, 2023, 15 (01)
  • [46] SAA suppresses α-PD-1 induced anti-tumor immunity by driving TH2 polarization in lung adenocarcinoma
    Xin Wang
    Shaodi Wen
    Xiaoyue Du
    Yihan Zhang
    Xiao Yang
    Renrui Zou
    Bing Feng
    Xiao Fu
    Feng Jiang
    Guoren Zhou
    Zi Liu
    Wei Zhu
    Rong Ma
    Jifeng Feng
    Bo Shen
    Cell Death & Disease, 14
  • [47] Improved survival with erdafitinib (JNJ-42756493) and PD-1 blockade mediated by enhancement of anti-tumor immunity in an FGFR2-driven genetically engineered mouse model of lung cancer
    Palakurthi, Sangeetha
    Kuraguchi, Mari
    Zacharek, Sima
    Liu, Jeff
    Bonal, Dennis
    Huang, Wei
    Depeaux, Kristin
    Dhaneshwar, Abha
    Regan, Sam
    Bailey, Dyane
    Gowaski, Martha
    Zheng, Mei
    Bronson, Roderick
    Ferrante, Catherine
    Zudaire, Enrique
    Laquerre, Sylvie
    Bittinger, Mark
    Paul, Kirschmeier
    Packman, Kathryn
    Verona, Raluca I.
    Wong, Kwok-Kin
    Lorenzi, Matthew V.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
  • [48] UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity
    He, Chuan
    Xing, Xixin
    Chen, Hsin-Yi
    Gao, Minling
    Shi, Jie
    Xiang, Bolin
    Xiao, Xiangling
    Sun, Yishuang
    Yu, Haisheng
    Xu, Gaoshan
    Yao, Yingmeng
    Xie, Zuosong
    Xing, Yujie
    Budiarto, Bugi Ratno
    Chen, Shih-Yu
    Gao, Yang
    Lee, Yu-Ru
    Zhang, Jinfang
    MOLECULAR CELL, 2024, 84 (06) : 1120 - 1138.e8
  • [49] Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition
    Hilberg, Frank
    Reschke, Markus
    Hofmann, Marco
    Kraut, Norbert
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S813 - S813
  • [50] Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Topalian, Suzanne L.
    Drake, Charles G.
    Pardoll, Drew M.
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) : 207 - 212
12345